26 February 2016 - the FDA has approved Gazyva (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyva alone as a new treatment for people with follicular lymphoma who did not respond to a rituximab-containing regimen, or whose follicular lymphoma returned after such treatment.

For more details, go to: http://www.gene.com/media/news-features/fda-approves-new-option-for-certain-people-with-previously-treated-follicular-lymphoma